PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
Negative R&D growth (spending reduction) needs careful analysis. Benjamin Graham would examine impact on competitive position.
-6.73%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
55.79%
Other expenses growth above 20% signals concerning cost expansion. Seth Klarman would scrutinize unusual items.
-5.86%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-5.86%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
-72.88%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
55.79%
D&A growth above 10% signals heavy asset expansion. Seth Klarman would demand evidence of future payoff.
-143.43%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
5.86%
Operating income growth 4-8% suggests moderate improvement. Benjamin Graham would check quality of earnings.
No Data
No Data available this quarter, please select a different quarter.
-101.24%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-142.73%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-72.88%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
-142.73%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-120.58%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-120.58%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
10.21%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
10.21%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.